Use of Sodium Glucose Transporter 2 Inhibitors in the treatment of heart failure: a literature review

Authors

DOI:

https://doi.org/10.33448/rsd-v11i6.29361

Keywords:

Sodium-glucose transporter 2 inhibitors; Heart failure; Treatment; Teaching.

Abstract

Heart failure (HF) is a complication that may be present in patients with type 2 diabetes mellitus associated with increased risks of morbidity and mortality. HF is common and associated with a poor prognosis, despite advances in treatment. The main biological processes that characterize heart failure with preserved ejection fraction are systemic inflammation, accumulation of epicardial adipose tissue, rarefaction of coronary microcirculation, myocardial fibrosis and vascular stiffness. The resulting impairment of left ventricular and aortic distensibility (especially accompanied by impaired glomerular function and sodium retention) causes increased cardiac filling pressures and exertional dyspnea despite relative preservation of left ventricular ejection fraction. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are one of the classes of glucose-lowering therapies that have demonstrated multi-system health benefits. The three inhibitors that are used are: empaglifozin, canaglifozin and dapagliflozin. Empaglifozin reduced the risk of pump failure and sudden death, the two most common modes in patients with heart failure. Regardless of their actions on blood glucose, SGLT2 inhibitors exert a wide range of biological effects including actions to inhibit cardiac inflammation and fibrosis, antagonize sodium retention, and improve glomerular function that may ameliorate the pathophysiological disorders of heart failure.

References

Anker, S. D., Butler, J., Filippatos, G. S., Jamal, W., Salsali, A., Schnee, J., Kimura, K., Zeller, C., George, J., Brueckmann, M., Zannad, F., Packer, M., Packer, M., Anker, S. D., Butler, J., Filippatos, G. S., Zannad, F., George, J., Brueckmann, M., & Perrone, S. (2019). Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial. European Journal of Heart Failure, 21(10), 1279–1287. https://doi.org/10.1002/ejhf.1596

Bocchi, E. A., Biolo, A., Moura, L. Z., Figueiredo, J. A., Montenegro, C. E. L., & Albuquerque, D. C. de. (2021). Tópicos Emergentes em Insuficiência Cardíaca: Inibidores do Cotransportador Sódio-Glicose 2 (iSGLT2) na IC. Arquivos Brasileiros de Cardiologia, 116(2), 355–358. https://doi.org/10.36660/abc.20210031

Certíková Chábová, Vera, & Zakiyanov, O. (2022). Sodium Glucose Cotransporter-2 Inhibitors: Spotlight on Favorable Effects on Clinical Outcomes beyond Diabetes. Int. J. Mol. Sci. (Online), -. https://pesquisa.bvsalud.org/portal/resource/pt/mdl-35269954

DeSa, T., & Gong, T. (2021). SGLT2 inhibitors: a new pillar of the heart failure regimen. Rev Cardiovasc Med, 1253–1269. https://pesquisa.bvsalud.org/portal/resource/pt/mdl-34957768

Fadiran, O., & Nwabuo, C. (2021). The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure. Cureus, e19379–e19379. https://pesquisa.bvsalud.org/portal/resource/pt/mdl-34925982

Fukuta, H., Hagiwara, H., & Kamiya, T. (2021). Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A protocol for meta-analysis. Medicine (Baltimore), e28448–e28448. https://pesquisa.bvsalud.org/portal/resource/pt/mdl-34941199

Keller, D. M., Ahmed, N., Tariq, H., Walgamage, M., Walgamage, T., Mohammed, A., Chou, J. T.-T., Kaluzna-Oleksy, M., Lesiak, M., & Straburzynska-Migaj, E. (2022). SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure-A Concise Review. -. https://pesquisa.bvsalud.org/portal/resource/pt/mdl-35329796

Lioudaki, E., Joslin, J. R., Trachanatzi, E., & Androulakis, E. (2022). The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneys. Rev Cardiovasc Med, 82–82. https://pesquisa.bvsalud.org/portal/resource/pt/mdl-35345249

March, K. L., Lukas, J. G., Berei, T. J., Shah, S. P., & Cave, B. E. (2022). SGLT-2 Inhibitor Use in Heart Failure: A Review for Nurses. Crit Care Nurs Q, 189–198. https://pesquisa.bvsalud.org/portal/resource/pt/mdl-35212658

McMurray, J. J. V., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Bengtsson, O., Ponikowski, P., Sabatine, M. S., Sjöstrand, M., Solomon, S. D., McMurray, J. J., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., & Ponikowski, P. (2019). A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF). European Journal of Heart Failure, 21(5), 665–675. https://doi.org/10.1002/ejhf.1432

McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., Böhm, M., Chiang, C.-E., Chopra, V. K., de Boer, R. A., Desai, A. S., Diez, M., Drozdz, J., Dukát, A., Ge, J., & Howlett, J. G. (2019). Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 381(21), 1995–2008. https://doi.org/10.1056/nejmoa1911303

Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., Jamal, W., Kimura, K., Schnee, J., Zeller, C., Cotton, D., Bocchi, E., Böhm, M., Choi, D.-J., Chopra, V., & Chuquiure, E. (2020). Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine, 383(15), 1413–1424. https://doi.org/10.1056/nejmoa2022190

Packer, M., Butler, J., Filippatos, G. S., Jamal, W., Salsali, A., Schnee, J., Kimura, K., Zeller, C., George, J., Brueckmann, M., Anker, S. D., Zannad, F., Packer, M., Anker, S. D., Butler, J., Filippatos, G., Zannad, F., George, J., Brueckmann, M., & Perrone, S. (2019). Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial. European Journal of Heart Failure, 21(10), 1270–1278. https://doi.org/10.1002/ejhf.1536

Pandey, A. K., Dhingra, N. K., Hibino, M., Gupta, V., & Verma, S. (2022). Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis. ESC Heart Fail, 942–946. https://pesquisa.bvsalud.org/portal/resource/pt/mdl-35112512

Salah, H. M., Al'Aref, Subhi J, Khan, M. S., Al-Hawwas, M., Vallurupalli, S., Mehta, J. L., Paul, M. J., Greene, S. J., McGuire, D. K., Lopes, R. D., & Fudim, M. (2022). Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol, 20–20. https://pesquisa.bvsalud.org/portal/resource/pt/mdl-35123480

Saucedo-Orozco, H., Voorrips, S. N., Yurista, S. R., de Boer, R. A., & Westenbrink, B. D. (2022). SGLT2 Inhibitors and Ketone Metabolism in Heart Failure. Journal of Lipid and Atherosclerosis, 11(1), 1. https://doi.org/10.12997/jla.2022.11.1.1

Seferović, P. M., Fragasso, G., Petrie, M., Mullens, W., Ferrari, R., Thum, T., Bauersachs, J., Anker, S. D., Ray, R., Çavuşoğlu, Y., Polovina, M., Metra, M., Ambrosio, G., Prasad, K., Seferović, J., Jhund, P. S., Dattilo, G., Čelutkiene, J., Piepoli, M., & Moura, B. (2020). Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 22(9), 1495–1503. https://doi.org/10.1002/ejhf.1954

Spertus, J. A., Birmingham, M. C., Nassif, M., Damaraju, C. V., Abbate, A., Butler, J., Lanfear, D. E., Lingvay, I., Kosiborod, M. N., & Januzzi, J. L. (2022). The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nature Medicine. https://doi.org/10.1038/s41591-022-01703-8

Vaduganathan, M., & Januzzi, J. L. (2019). Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors. The American Journal of Cardiology, 124, S20–S27. https://doi.org/10.1016/j.amjcard.2019.10.026

Varadhan, A., Stephan, K., Gupta, R., Vyas, A. V., Ranchal, P., Aronow, W. S., Hawwa, N., & Lanier, G. M. (2022). Growing role of SGLT2i in heart failure: evidence from clinical trials. Expert Rev Clin Pharmacol, 147–159. https://pesquisa.bvsalud.org/portal/resource/pt/mdl-35264076

Whittemore, R., & Knafl, K. (2005). The integrative review: updated methodology. Journal of Advanced Nursing, 52(5), 546–553. https://doi.org/10.1111/j.1365-2648.2005.03621.x

Zannad, F., Ferreira, J. P., Pocock, S. J., Anker, S. D., Butler, J., Filippatos, G., Brueckmann, M., Ofstad, A. P., Pfarr, E., Jamal, W., & Packer, M. (2020). SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. The Lancet, 396(10254), 819–829. https://doi.org/10.1016/s0140-6736(20)31824-9

Published

02/05/2022

How to Cite

BIGARAN, L. T. .; SAAB, V. .; FERREIRA, T. C. .; PAULA, L. B. de .; BARBOSA, T. C. .; MANTELO, G. M. .; SOUZA JUNIOR, S. L. de .; SANTOS, P. E. S. dos .; LEITAO, G. G. A. S. .; MAIA, A. K. da S. .; PAGLIARANI, G. H. .; FEDOCCI, E. M. M. . Use of Sodium Glucose Transporter 2 Inhibitors in the treatment of heart failure: a literature review. Research, Society and Development, [S. l.], v. 11, n. 6, p. e42411629361, 2022. DOI: 10.33448/rsd-v11i6.29361. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/29361. Acesso em: 18 may. 2022.

Issue

Section

Health Sciences